A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects With Chronic HCV GT1, GT4, and GT6 Infection Who Are Co-Infected With HIV

Trial Profile

A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naive Subjects With Chronic HCV GT1, GT4, and GT6 Infection Who Are Co-Infected With HIV

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms C-EDGE CO-INFXN; C-EDGE COINFECTION
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Jan 2016 In January 2016, the US FDA approved elbasvir and grazoprevir (Zepatier) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients, according to an FDA media release.
    • 18 Dec 2015 According to Merck & Co media release, the Committee for Medicinal Products for Human Use (CHMP) of the EMA has advised the company that the MAA for grazoprevir/elbasvir will be reviewed on a standard timetable instead of accelerated timeline.
    • 14 Nov 2015 Results of integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from this and 5 other phase II and III trials will be presented at The Liver Meeting 2015, according to a Merck & Co media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top